Skip to content

CorMedix CRMD Deferred Tax Assets, Net of Valuation Allowance

Deferred Tax Assets, Net of Valuation Allowance at other companies

Merck & Co. logo
Merck & Co.MRK
Abbott logo
AbbottABT
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL

Other financials

Income statement

See full
Revenue$127.4M+226%
Gross profit$115.4M+207%
Operating income$63.7M+216%
Net income$38.6M+87.0%
EPS (diluted)$0.43+43.3%

Balance sheet

See full
Cash & equivalents$179.1M+170%
Total debt$4.3M+729%
Total equity$437.0M+280%
Total assets$815.6M+445%

Cash flow

See full
Operating cash flow$42.4M+115%
CapEx$729.0K+7,190%
Free cash flow$41.7M+111%

Valuation

See full
Market cap$605.65M-34.4%
P/E3.4×
P/S1.5×-9.6×

Profitability

See full
Gross margin91.9%-3.5pp
Operating margin48.4%
Net margin45.2%
FCF margin48.7%+38.8pp

Returns & leverage

See full
Return on equity65.6%
Debt / equity0.0×
Current ratio-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsNet.

The official record: CorMedix’s 10-K, filed March 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's deferred tax assets, net of valuation allowance.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CorMedix's deferred tax assets, net of valuation allowance?
CorMedix (CRMD) reported deferred tax assets, net of valuation allowance of $67.76M in Q4 2025.